Follicular Thyroid Cancer Treatment

Follicular thyroid cancer (FTC) is the second most common thyroid malignancy, accounting for approximately 10-15% of all thyroid cancers diagnosed worldwide. While it shares a favourable overall prognosis with papillary thyroid cancer, FTC presents unique diagnostic and surgical challenges that require a surgeon experienced in evidence-based decision-making. At THANC Hospital in Chennai, Dr. Vidhyadharan Sivakumar performs follicular thyroid cancer surgery with a precision that reflects his MCh in Head & Neck Surgery, FEB-ORL HNS (European Board certification), FICRS, Gold Medal in MS (ENT), and over 3000 head and neck surgeries -- ensuring neither under-treatment of aggressive disease nor over-treatment of low-risk tumours.

Understanding Follicular Thyroid Cancer

Follicular thyroid cancer arises from the same follicular epithelial cells as papillary thyroid cancer, but it differs in several fundamental ways that directly impact diagnosis and treatment. While papillary thyroid cancer is defined by characteristic nuclear features and can be diagnosed readily on fine needle aspiration cytology, follicular thyroid cancer is defined by its pattern of invasion -- specifically capsular and vascular invasion -- which can only be assessed on the final surgical specimen. This critical distinction means that FTC cannot be diagnosed before surgery on FNAC alone, creating a unique diagnostic pathway that requires surgical excision for definitive diagnosis.

FTC typically presents in patients aged 40-60 years with a slight female predominance, though the gender difference is less pronounced than in papillary thyroid cancer. In India, FTC accounts for a significant proportion of thyroid cancers, particularly in regions with historically lower iodine intake, as iodine deficiency has been associated with a higher ratio of follicular to papillary thyroid cancers. Understanding the complete landscape of thyroid cancer surgery provides essential context for patients facing a follicular thyroid neoplasm diagnosis.

FTC's biological behaviour diverges from PTC in clinically important ways. FTC spreads through the bloodstream to lungs and bones rather than through lymphatics to lymph nodes. Cervical lymph node metastases are uncommon (<10% vs. 30-80% in PTC). FTC has a higher rate of distant metastases at presentation (10-15% vs. 2-5% for PTC), with bone metastases sometimes being the presenting complaint.

Types and Classification

The biological aggressiveness of follicular thyroid cancer is primarily determined by the degree of invasion observed on histopathological examination of the surgical specimen. This classification directly determines surgical extent, the need for additional treatment, and the intensity of long-term surveillance.

Minimally invasive FTC (capsular invasion only) shows limited capsular penetration without vascular invasion. It has an excellent prognosis with 10-year disease-specific survival exceeding 97%, and lobectomy alone is typically sufficient treatment.

Minimally invasive FTC (limited angioinvasion) demonstrates capsular invasion with fewer than 4 invaded vessels. This intermediate category has approximately 95% 10-year survival, with completion thyroidectomy and radioactive iodine therapy considered on a case-by-case basis.

Encapsulated angioinvasive FTC shows capsular invasion with 4 or more invaded blood vessels. This carries a meaningful risk of distant metastases, with approximately 70-80% 10-year survival, and requires total thyroidectomy and radioactive iodine therapy.

Widely invasive FTC demonstrates extensive invasion through the tumour capsule into surrounding thyroid tissue, blood vessels, and potentially extrathyroidal structures. This carries the highest risk of distant metastases to lungs, bones, liver, and brain, with 10-year survival of approximately 50-70%.

Hurthle cell carcinoma (oncocytic carcinoma) is now recognised as a distinct entity in the 2022 WHO classification. More aggressive than conventional FTC with lower RAI avidity (30-40% RAI-refractory) and higher recurrence rates, it requires total thyroidectomy regardless of tumour size.

Causes and Risk Factors

Several factors contribute to the development of follicular thyroid cancer:

• Iodine deficiency: Historically, regions with lower iodine intake had higher rates of FTC relative to PTC. India's universal salt iodisation programme has reduced this disparity, but regional variations persist.
• Age: FTC tends to present at a slightly older age (40-60 years) compared to PTC, with more aggressive behaviour in older patients.
• Radiation exposure: Prior head and neck radiation increases the risk of all differentiated thyroid cancers including FTC.
• Genetic factors: RAS mutations (NRAS, HRAS, KRAS) are the most common genetic alterations in FTC, present in approximately 40-50% of cases. PAX8-PPARG rearrangement is found in approximately 30-35% and is relatively specific to this subtype.
• Cowden syndrome: This hereditary condition caused by PTEN gene mutations is associated with an increased risk of follicular thyroid cancer, along with breast, endometrial, and other cancers.
• Female sex: Women are affected approximately 2-3 times more frequently than men, though the gender difference is less marked than in PTC.

Signs and Symptoms

Follicular thyroid cancer typically presents with subtle findings:

• Solitary thyroid nodule: A single, firm, well-defined nodule that may be slow-growing. Unlike the often multifocal presentation of PTC, FTC is usually unifocal.
• Gradual thyroid enlargement: Progressive growth of a previously stable nodule should raise concern.
• Bone pain or pathological fracture: In rare but clinically significant cases, the first presentation is a bone metastasis -- particularly in the pelvis, femur, spine, or skull.
• Pulmonary symptoms: Rarely, diffuse pulmonary metastases cause cough or dyspnea.
• Local compressive symptoms: Large FTC tumours may cause dysphagia, neck pressure, or rarely hoarseness.

The absence of palpable cervical lymph node enlargement in the presence of a thyroid nodule is actually more consistent with FTC than PTC, as lymph node spread is uncommon in follicular carcinoma.

Diagnosis at THANC Hospital

The diagnostic pathway for follicular thyroid cancer is inherently different from other thyroid cancers because of the FNAC limitation. Dr. Vidhyadharan's FEB-ORL HNS European Board certification reflects the rigorous evidence-based training that is essential for navigating this diagnostic complexity.

Ultrasound assessment evaluates nodule characteristics. FTC nodules often appear solid, isoechoic or slightly hypoechoic, well-defined with a thick irregular halo, and with increased internal vascularity -- but lacking the microcalcifications typical of PTC. However, ultrasound alone cannot reliably distinguish follicular adenoma from carcinoma.

FNAC and the Bethesda IV challenge: When FNAC reports Bethesda Category IV -- "Follicular Neoplasm" or "Suspicious for Follicular Neoplasm" -- the malignancy risk is approximately 25-40%. The majority of Bethesda IV nodules are actually benign follicular adenomas, but definitive distinction requires surgical excision. Understanding thyroid nodule evaluation and the Bethesda system helps patients navigate this diagnostic uncertainty.

Molecular testing (ThyroSeq v3, Afirma GSC) can provide additional risk stratification for Bethesda IV nodules. Identifying RAS mutations or PAX8-PPARG rearrangement increases suspicion for FTC but does not eliminate the need for surgical excision. Dr. Vidhyadharan integrates molecular testing results into surgical planning when available.

The diagnostic lobectomy is the standard approach for Bethesda IV nodules. The entire lobe is removed and examined for capsular and vascular invasion. Frozen section has poor sensitivity for this distinction, and the definitive diagnosis requires examination of the entire tumour capsule, with final results available in 7-10 days.

Preoperative distant disease screening for larger follicular neoplasms (>4 cm) or those with concerning features may include CT chest, bone scan, or PET-CT, along with baseline thyroglobulin levels.

How Dr. Vidhyadharan Treats Follicular Thyroid Cancer

At THANC Hospital, Dr. Vidhyadharan performs follicular thyroid cancer surgery following a stepwise, evidence-based pathway tailored to each patient's specific pathology. His approach is informed by his MCh in Head & Neck Surgery, FEB-ORL HNS certification, and over 3000 head and neck surgeries.

Step 1: Diagnostic Lobectomy

All patients with Bethesda IV cytology undergo thyroid lobectomy as the initial surgical procedure. This serves as both diagnosis and treatment if the final pathology shows a benign adenoma or minimally invasive FTC without significant vascular invasion. Dr. Vidhyadharan performs all lobectomies with IONM nerve monitoring to ensure recurrent laryngeal nerve preservation. The surgery is performed through a cosmetic collar incision and typically requires a 1-day hospital stay.

Step 2: Histopathological Assessment

The final pathology report -- available within 7-10 days -- determines subsequent management. This is the critical juncture where Dr. Vidhyadharan's evidence-based approach prevents both under-treatment and over-treatment:

Step 3: Completion Thyroidectomy (When Indicated)

For patients with intermediate or high-risk features, completion thyroidectomy is performed within 2-4 weeks, enabling radioactive iodine therapy, reliable thyroglobulin monitoring, and whole-body iodine scanning. This technically demanding revision surgery benefits from Dr. Vidhyadharan's extensive experience and routine IONM use for safe nerve preservation in the previously operated field.

Step 4: Radioactive Iodine Therapy

RAI therapy is administered after total thyroidectomy for encapsulated angioinvasive FTC with significant vascular invasion, widely invasive FTC, and FTC with distant metastases. FTC cells generally retain good radioactive iodine avidity, making RAI an effective treatment for both thyroid bed remnant ablation and distant metastatic disease. The decision is coordinated with nuclear medicine specialists at THANC Hospital.

Papillary vs. Follicular Thyroid Cancer: Key Differences

What to Expect: Your Treatment Journey

At THANC Hospital, Dr. Vidhyadharan guides patients through a clearly defined treatment pathway for follicular thyroid neoplasms.

Initial consultation includes review of all available investigations -- ultrasound images, FNAC reports, molecular test results, and blood work. A detailed neck examination and flexible laryngoscopy are performed. Dr. Vidhyadharan explains that a lobectomy is needed for definitive diagnosis and that the final management plan depends entirely on pathology results.

Lobectomy day: The surgery is performed under general anaesthesia through a cosmetic collar incision. IONM monitors the recurrent laryngeal nerve throughout. Surgery typically takes 1-1.5 hours. Most patients are discharged the following day with minimal pain and early return to oral diet.

Awaiting results (7-10 days): Dr. Vidhyadharan ensures timely communication of results and schedules a dedicated consultation to discuss findings, explain the diagnosis clearly, and outline next steps. If completion thyroidectomy is needed, it is scheduled promptly.

Completion thyroidectomy (if needed): Performed 2-4 weeks after the initial lobectomy, this surgery removes the remaining thyroid lobe with IONM support. Hospital stay is 1-2 days.

Multidisciplinary review: The tumour board at THANC Hospital -- including nuclear medicine, pathology, endocrinology, and oncology -- determines whether radioactive iodine therapy is indicated based on the complete pathological picture.

For patients preparing for thyroid cancer surgery, understanding the stepwise nature of FTC treatment helps manage expectations during the diagnostic phase.

Recovery and Rehabilitation

Recovery from follicular thyroid cancer surgery follows a predictable course.

After lobectomy, most patients resume normal activities within 1-2 weeks. Thyroid function is monitored at 6-8 weeks to determine if levothyroxine supplementation is needed -- approximately 50-80% of lobectomy patients maintain adequate thyroid function with the remaining lobe.

After total or completion thyroidectomy, lifelong levothyroxine replacement is required. Calcium levels are monitored closely for temporary hypoparathyroidism, with supplementation provided and gradually tapered. Return to normal activities occurs within 2-3 weeks.

Voice preservation is a priority throughout. IONM use during both the initial lobectomy and any completion thyroidectomy minimises the risk of recurrent laryngeal nerve injury. Any postoperative voice changes are assessed with laryngoscopy and managed with speech therapy if needed.

Wound care involves keeping the cosmetic collar incision clean and dry, with removal of closure strips at 1-2 weeks. The scar matures over 6-12 months to a typically inconspicuous line.

The 7-10 day wait for pathology results can be stressful. Dr. Vidhyadharan and the THANC Hospital team provide clear communication at every stage to help patients and families navigate the process.

Outcomes and Prognosis

The prognosis for follicular thyroid cancer spans a wide spectrum based on the degree of invasion, making accurate histopathological classification essential:

• Minimally invasive FTC (capsular invasion only): Near-100% disease-specific survival at 10 years. Essentially cured by lobectomy alone.
• Minimally invasive FTC (limited angioinvasion, <4 vessels): 10-year survival approximately 95%. Excellent outcomes with appropriate treatment.
• Encapsulated angioinvasive FTC (4+ vessels): 10-year survival approximately 70-80%. Risk of distant metastases necessitates total thyroidectomy and RAI.
• Widely invasive FTC: 10-year survival approximately 50-70%. Higher risk of distant metastases, particularly to lungs and bones.

Key prognostic factors include patient age, tumour size, degree of vascular invasion, presence of distant metastases, and RAI responsiveness. Late recurrences beyond 10 years are possible, necessitating prolonged surveillance.

Why Choose Dr. Vidhyadharan at THANC Hospital

Follicular thyroid cancer demands a surgeon who combines precise surgical technique with nuanced evidence-based decision-making -- the difference between appropriate lobectomy-only management and necessary completion thyroidectomy hinges on expert interpretation of histopathological findings. Dr. Vidhyadharan Sivakumar brings:

• FEB-ORL HNS (European Board certification) -- the highest European standard of head and neck surgical qualification, with rigorous examination of evidence-based practice.
• MCh (Head & Neck Surgery) from Amrita Institute -- super-speciality training in oncological thyroid surgery.
• Gold Medal in MS (ENT) from Annamalai University -- demonstrating academic excellence and deep understanding of surgical anatomy.
• Over 3000 head and neck surgeries -- providing the experience base for both diagnostic lobectomies and technically demanding completion thyroidectomies.
• Routine IONM nerve monitoring -- essential for both initial and revision thyroid surgery to ensure voice preservation.
• FICRS certification -- fellowship training at Royal Adelaide Hospital, Australia, as part of training across 8 countries.
• Co-editor, "Comprehensive Management of Head and Neck Cancer" (Jaypee, 2021) -- contributing to the academic knowledge base that informs clinical practice.
• Multidisciplinary coordination at THANC Hospital with nuclear medicine, pathology, endocrinology, and oncology for comprehensive FTC management.

For a personalised assessment and treatment plan, schedule a consultation with Dr. Vidhyadharan Sivakumar at THANC Hospital, Kilpauk, Chennai.

Phone: +91 73059 53378 Location: THANC Hospital, 747 Poonamallee High Road, Kilpauk, Chennai 600010 Book an Appointment